Capitainer announces collaboration with AstraZeneca
The Swedish medtech company Capitainer AB today announces a research collaboration with AstraZeneca. AstraZeneca R&D Gothenburg will use a novel device from Capitainer to develop protocols for biomarkers relevant to AstraZeneca’s clinical drug programs.The collaboration aims to develop protocols for biomarkers relevant to AstraZeneca’s clinical drug programs based on Capitainer’s novel self-sampling product delivering cell-free blood. This allows for new patient-centric sampling solutions to be implemented.Implementing remote quantitative microsampling methods provides an opportunity to